Genes, Vol. 12, Pages 329: Quantifying Fetal Reprogramming for Biomarker Development in the Era of High-Throughput Sequencing

Genes, Vol. 12, Pages 329: Quantifying Fetal Reprogramming for Biomarker Development in the Era of High-Throughput Sequencing Genes doi: 10.3390/genes12030329 Authors: Fu-Sheng Chou Krystel Newton Pei-Shan Wang Gestational hypertensive disorders continue to threaten the well-being of pregnant women and their offspring. The only current definitive treatment for gestational hypertensive disorders is delivery of the fetus. The optimal timing of delivery remains controversial. Currently, the available clinical tools do not allow for assessment of fetal stress in its early stages. Placental insufficiency and fetal growth restriction secondary to gestational hypertensive disorders have been shown to have long-term impacts on offspring health even into their adulthood, becoming one of the major focuses of research in the field of developmental origins of health and disease. Fetal reprogramming was introduced to describe the long-lasting effects of the toxic intrauterine environment on the growing fetus. With the advent of high-throughput sequencing, there have been major advances in research attempting to quantify fetal reprogramming. Moreover, genes that are found to be differentially expressed as a result of fetal reprogramming show promise in the development of transcriptional biomarkers for clinical use in detecting fetal response to placental insufficiency. In this review, we will review key pathophysiology in the development of placental insufficiency, existing lit...
Source: Genes - Category: Genetics & Stem Cells Authors: Tags: Review Source Type: research